The Oslo Cancer Cluster Innovation Park in Norway has opened. A $122.8 million, public-private investment, the Innovation Park brings together the research, healthcare and industry partners in the Oslo oncology value chain with the Ullern High School.

The vision of the Oslo Cancer Cluster Innovation Park is to create a leading European environment for education, research and industry within oncology, while also shortening the time it takes to develop new cancer medication and diagnostics.

The founder of the Oslo Cancer Cluster Innovation Park, Jónas Einarsson, said, “The Innovation Park includes Ullern High School, The Cancer Registry of Norway, Oslo Cancer Cluster Incubator and Institute for Medical Informatics and Pathology at Oslo University Hospital, as well as global biopharmaceutical and biotech companies.”

The total investment in the building is $122.8 million; one-third founded by Siva, the Norwegian state’s vehicle for developing new businesses and knowledge communities, and two-thirds private funding raised in collaboration by OBOS, Industrifinans, Radium Hospitalets Legater and Utstillingsplassen Eiendom.

Unlike other Innovation Parks, the Oslo Cancer Cluster Innovation Park will integrate a High School, namely Ullern High School. This will give the students the opportunity to hear guest lectures from oncology researchers and industry leaders, do internships at Oslo University Hospital and the other members of Oslo Cancer Cluster. “In this way, we hope to inspire future generations of researchers,” said Einarsson.